AnaMar AB: AnaMar reports positive phase I data for its phase II ready compound AM1476 to treat fibrosis

AnaMar, a clinical─stage biotech company, announces positive results from its phase I study, and the completion of phase II enabling pre─clinical studies for its initial orphan indication in systemic sclerosis (SSc)